Floatz logo

Nivolumab

Castration-Resistant Prostate Carcinoma

Explore 215 assets in Castration-Resistant Prostate Carcinoma →
Floatz Rating
B63/100
Confidence
Indicative
v0.2
Sponsor
Rana McKay, MD
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05502315CT.gov
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
—Recruiting———
NCT05169684CT.gov
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
—Terminated———
NCT05176483CT.gov
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
—Recruiting———
NCT04477512CT.gov
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
—Completed———
NCT04717154CT.gov
Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer
—Completed———
NCT03878524CT.gov
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
—Terminated———
NCT05655715CT.gov
Checkpoint Inhibitors and SBRT for MCRPC
—Completed———
NCT04159896CT.gov
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
—Terminated———
NCT03815942CT.gov
VAccination in Early and ADvanced Prostate caNCEr
—Terminated———
NCT03554317CT.gov
COMbination of Bipolar Androgen Therapy and Nivolumab
—Completed———
Show 1 more trial
NCT00730639CT.gov
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Castration-Resistant Prostate Carcinoma

AssetSponsorPhaseRating
Nivolumab (this asset)Rana McKay, MDP2B · 63
DarolutamideBayerP4BBB
EnzalutamideProstate Cancer Clinical Trials ConsortiumP4BBB
PrednisoloneDing-Wei YeP4BBB
Radium Ra-223University of California, San FranciscoP4BB
CabozantinibRana McKay, MDP3BB
MevrometostatProstate Cancer Clinical Trials ConsortiumP3BB
PrednisoneJanssen Research & Development, LLCP4BB
AbirateroneAstraZenecaP4BB

+42 more in the Castration-Resistant Prostate Carcinoma cohort

Other indications for Nivolumab

IndicationSponsorPhaseRating
Renal Carcinoma—P4BBB · 72
Metastatic Melanoma—P4BB · 70
Non-Small Cell Lung Carcinoma—P4BB · 70

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Nivolumab in Castration-Resistant Prostate Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/nivolumab-castration-resistant-prostate-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →